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Previewssupplemented with excess proline ex-
hibited a reduced lifespan, whereas
supplementing proline to E. coli OP50
had no additional adverse effects on
longevity. However, it is likely that the
intermediate P5C and not proline itself is
toxic to the animal, because the detri-
mental effect of alh-6 mutation is lost
when the conversion of proline into this
compound is prevented by a perturbation
of PRODH/B0513.5. In the future, mass
spectrometry of different bacteria may
reveal whether they harbor different levels
of proline or P5C. Since both are E. coli
strains, it is unlikely that such differences
would result from major differences in
metabolic pathways. Rather, variations
in metabolic pathway genes may underlie
the observed effects. Exploring variation
in proline metabolism and other gene
activity or expression, bacterial genetic178 Cell Metabolism 19, February 4, 2014 ª2screens, or targeted mutagenesis of
candidate genes will be useful to unravel
the precise mechanism involved.
Altogether, this study provides an
important step forward in our apprecia-
tion of the effect different amino acids
can exert, whether it is the conversion of
proline central to this study, tryptophan
in nhr-114 mutants on the E. coli OP50
diet (Gracida and Eckmann, 2013), or
branched-chain amino acid metabolism
in response to the Comamonas diet
(Watson et al., 2013). C. elegans and its
bacterial diets will no doubt continue to
provide a powerful interspecies paradigm
to dissect the interactions between
specific genes and nutrients, and their
effects on development, fertility, and
aging. As with many other key findings
from the nematode, results may illuminate
how particular nutrients, such as amino014 Elsevier Inc.acids, affect cellular and organismal
physiology in health and disease in
humans as well.REFERENCES
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Age-related mitochondrial dysfunction is thought to contribute to mammalian aging, particularly in post-
mitotic tissues that rely heavily on oxidative phosphorylation. A new study (Gomes et al., 2013) shows that
reduced levels of nicotinamide adenine dinucleotide (NAD+) contribute to the mitochondrial decay asso-
ciated with skeletal muscle aging and that sirtuin 1 (SIRT1) modulates this process.Decreased mitochondrial function with
age has been documented in multiple
mammalian species. Studies on isolated
mitochondria from human muscle bi-
opsies or rodent muscles support the
existence of an intrinsic, aging-dependent
mitochondrial defect associated with
ATP production (Short et al., 2005), and
studies employing permeabilized muscle
fibers also demonstrate impaired mito-
chondrial function in aged humans
(Joseph et al., 2012). If mitochondrial
decay does indeed contribute to aging
phenotypes, interventions that preventor reverse such decay may improve
the quality of life of aged individuals. A
major roadblock to the development of
such interventions is that the specific
mechanisms of age-related mitochondrial
dysfunction are poorly understood. A role
formtDNAmutations has been postulated
due to the proximity of mtDNA and free
radical production sites in mitochondria.
Indeed, mice engineered to accumulate
mtDNA mutations at high levels display
multiple aging phenotypes (Kujoth et al.,
2005). However, the levels of mtDNA
point mutations and deletions found inmost tissues from aged humans or ani-
mals usually account for less than 1%
of the total mtDNA and are unlikely to
be major contributors to age-related
mitochondrial dysfunction. A reduction
in mtDNA copy number may be more
relevant, as it could lead to reduced
levels of mtDNA-encoded transcripts
and proteins, as reported in skeletal mus-
cle of older adults (Short et al., 2005).
Gomes et al. now provide insights into
the relationship between mtDNA, NAD+,
and the mitochondrial dysfunction of
aging (Gomes et al., 2013). The authors
Figure 1. Age-Dependent Decline in NAD+
Decreased NAD+ synthesis and increased NAD+ consumption with agemay both contribute to a decrease
in the NAD+ pool. A reduction in NAD+ levels leads to an age-related reduction of SIRT1 activity. Reduced
SIRT1 activity impacts mitochondrial function through at least two mechanisms: (1) a reduction in bio-
genesis secondary due to a reduction in PGC1-a activity and (2) an impairment of mitochondrial function
due to a reduction in mtDNA replication and transcription.
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Previewsreport progressive age-related reduction
in mtDNA-encoded transcripts in the
gastrocnemius (calf) muscle of mice.
Interestingly, a reduction in nuclear-
encoded mitochondrial genes was also
observed but appeared to lag behind the
loss of mtDNA-encoded transcripts by
several months. These transcriptional
alterations were associated with a decline
in mtDNA copy number and a decline
in ATP content, suggesting that these
events are causally linked. Since the
authors had previously linked sirtuin 1
(SIRT1) activity with increased mitochon-
drial biogenesis through PGC1-a deace-
tylation, they tested whether these age-
related mitochondrial alterations might
be due to reduced SIRT1 activity, using
an elegant tissue-specific (SIRT1 induc-
ible knockout [iKO]) transgenic model
to generate mice that lacked SIRT1 in
skeletal muscle. Interestingly, this led to
reduced expression of mtDNA-encoded
genes, but not nuclear-encoded mito-
chondrial genes. The intervention also
had no impact on mtDNA mass, which
is expected to be reduced if the
SIRT1-PGC1-a pathway of mitochondrialbiogenesis is impaired. Thus, under basal
conditions (i.e., not under caloric restric-
tion or exercise) the SIRT1-PGC1-a
pathwaymay not be themain determinant
of mitochondrial biogenesis. However,
since NAD+ is required for SIRT1 activity,
the authors next examined the levels
of NAD+ in tissues of aged mice and
found a dramatic decrease in NAD+ with
aging. Furthermore, overexpression of
nicotinamide mononucleotide adenylyl
transferase (NMNAT1), a nuclear NAD+
synthetic enzyme, in skeletal muscle of
10- to 12-month-old mice significantly
increased the levels of NAD+ and, impor-
tantly, the expression of mtDNA-encoded
genes. In vitro studies with myoblasts
suggest that the role of NMNAT1 in this
system is dependent on SIRT1. Strikingly,
short-term feeding of NMN (an NAD+ pre-
cursor) to old mice reversed several
biochemical parameters associated with
mitochondrial aging. Caloric restriction,
which retards aging and induces SIRT1,
also prevented the age-related NAD+
decline and maintained mtDNA gene
expression. Thus, variations in NAD+
levels play a critical role in mtDNA tran-Cell Metabolism 19scription and mitochondrial aging, and
this role appears to be mediated at least
in part through SIRT1.
The mechanism by which SIRT1 and
NAD+ control mtDNA transcription is not
fully understood. Gomes et al. suggest
that NAD+-dependent SIRT1 activity reg-
ulates the nuclear expression of mito-
chondrial transcription factor A (TFAM),
which plays an essential role in mainte-
nance, expression, and organization of
mitochondrial DNA (Gomes et al., 2013).
The actual acetylated protein targets of
the SIRT1 deacetylase responsible for
TFAM expression were not identified.
However, the authors implicated a path-
way involving hypoxia-inducible factor
1a (HIF1a), c-Myc, and von Hippel-Lindau
(VHL) E3 ubiquitin ligase that recognizes
hydroxylated proline residues on HIF1a
for degradation by the proteosome
(Gomes et al., 2013). The authors propose
that lowered NAD+ with age decreases
the ability of VHL to downregulate
HIF1a, which would compete with the
opposing functions of c-Myc on the
TFAM promoter. SIRT1 expression had
no effect on VHL promoter activity, but
VHL protein levels positively correlated
with SIRT1 protein, suggesting that
SIRT1 directly or indirectly controls VHL
at the posttranscriptional level. The
simplest explanation is that VHL is a direct
acetylation target of SIRT1; however, no
data were shown to support this idea.
Clearly, additional experiments are
needed to fully elucidate the molecular
role played by SIRT1 during the age-
dependent decline in NAD+ levels.
The observation that NMN supple-
mentation can restore NAD+ levels and
markers of mitochondrial function that
decline with age prompts a number of
interesting questions. Why does NAD+
decline with age? The levels of NAD+ are
governed by the cellular redox state (i.e.,
NAD+/NADH), the rate of NAD+ synthesis,
and the rate of NAD+ consumption
(Figure 1). NAD+ and NADH are rapidly
interchangeable, and levels of NADH are
considerably lower than those of NAD+,
making this redox ratio a less dramatic
explanation for age-dependent decline
of NAD+. However, a lowered NAD+/
NADH ratio is associated with aging
muscle, consistent with a possible link
(Pugh et al., 2013). The ability to rescue
mitochondrial function with NMN sug-
gests that the NAD+ salvage pathway is, February 4, 2014 ª2014 Elsevier Inc. 179
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reaction catalyzed by nicotinamide phos-
phoribosyltransferase (NAMPT), which
generates NMN as a product. On the
other hand, the ability of NMNAT1 to
restore mitochondrial function suggests
that NMNAT1 levels are rate-limiting for
sustaining adequate NAD+ levels. These
questions could be addressed by exam-
ining the ability of NAMPT to rescue mito-
chondrial function and whether upstream
NAD+ precursors (e.g., nicotinamide and
nicotinamideriboside) function as well as
NMN. Another interesting explanation
for declining NAD+ may be that NAD+-
consuming enzymes are hyperstimulated.
A likely candidate is poly(ADP-ribose)
polymerase-1, PARP1, which depletes
nuclear and cytoplasmic NAD+ upon
genotoxic stress (Cipriani et al., 2005).
Accumulating DNA damage as cells age
might chronically stimulate the NAD+-
consuming activity of PARP (Massudi
et al., 2012), leading to reduced NAD+
levels and SIRT1 activity, which is critical180 Cell Metabolism 19, February 4, 2014 ª2for TFAM expression and mitochondrial
oxidative phosphorylation (OXPHOS)
expression (Figure 1). In that case, PARP
inhibition might restore mitochondrial
function. Ultimately, theremay bemultiple
causes for age-dependent decline in
NAD+, including a metabolic shift to pro-
cesses that disfavor a high NAD+/NADH
ratio, defective NAD+ salvage, or over-
consumption of NAD+ cleaving enzymes,
like PARP, CD38, and even sirtuins
(Braidy et al., 2013). Importantly, the study
suggests that age-related mitochondrial
dysfunction is not due to the accumula-
tion of irreversible damage to macromole-
cules. Instead, the defect results in part
from a decline in the levels of a key coen-
zyme and therefore may be reversible.REFERENCES
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